[go: up one dir, main page]

GT200400218A - Formulaciones de liberacion sostenida. - Google Patents

Formulaciones de liberacion sostenida.

Info

Publication number
GT200400218A
GT200400218A GT200400218A GT200400218A GT200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A
Authority
GT
Guatemala
Prior art keywords
sustained release
release formulations
administration
formulations
sustained
Prior art date
Application number
GT200400218A
Other languages
English (en)
Inventor
Erick J Benjamin
Wendy A Dulin
Yanning Lin
Kai Zhuang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200400218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200400218A publication Critical patent/GT200400218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES DE DOSIS DE LIBERACION CONTROLADA Y SOSTENIDA DE COMPUESTOS DOPAMINERGICOS, EN PARTICULAR A APLINDORE, ESTAS FORMULACIONES SON UTILES PARA TRATAR ENFERMEDADES TALES COMO LA EZQUIZOFRENIA, ENFERMEDAD DE PARKINSON, SINDROME DE TOURETTE, PSICOSIS, HIPERPROLACTAMIA, ADICCION A DROGAAS Y MANIA AGUDA EN EL DESORDEN BIPOLAR.
GT200400218A 2003-10-29 2004-10-28 Formulaciones de liberacion sostenida. GT200400218A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51531503P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
GT200400218A true GT200400218A (es) 2005-06-06

Family

ID=34572826

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400218A GT200400218A (es) 2003-10-29 2004-10-28 Formulaciones de liberacion sostenida.

Country Status (21)

Country Link
US (5) US20050095292A1 (es)
EP (1) EP1675583B1 (es)
JP (1) JP5547865B2 (es)
KR (1) KR101409724B1 (es)
CN (2) CN102335116A (es)
AR (1) AR046222A1 (es)
AU (1) AU2004286855B2 (es)
BR (1) BRPI0415953B8 (es)
CA (1) CA2543045C (es)
ES (1) ES2405404T3 (es)
GT (1) GT200400218A (es)
IL (1) IL174958A (es)
MX (1) MXPA06004752A (es)
NO (1) NO20062004L (es)
PA (1) PA8616201A1 (es)
PE (1) PE20050484A1 (es)
RU (1) RU2376988C2 (es)
SG (1) SG147450A1 (es)
TW (1) TW200517106A (es)
WO (1) WO2005044262A1 (es)
ZA (1) ZA200603409B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102335116A (zh) 2003-10-29 2012-02-01 惠氏有限责任公司 包含aplindore和其衍生物的缓释药物组合物
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
MX2008002512A (es) * 2005-08-26 2008-04-03 Bpsi Holdings Inc Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
WO2010072703A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
ES2751920T3 (es) 2011-01-07 2020-04-02 Novartis Ag Formulaciones inmunosupresoras
AU2012297569B2 (en) 2011-08-16 2017-11-09 Baker Heart and Diabetes Institute Controlled-release formulation
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
EP2887935A1 (en) * 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
BR112017013015A2 (pt) 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
JP7096441B2 (ja) * 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
CN113559074B (zh) * 2020-06-28 2023-04-21 海创药业股份有限公司 一种喹啉类化合物缓释片及其制备方法
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
WO1991013872A1 (en) 1990-03-15 1991-09-19 The Upjohn Company Therapeutically useful heterocyclic indole compounds
JP2600978B2 (ja) * 1990-05-25 1997-04-16 日産自動車株式会社 サスペンションのアッパリンク支持部構造
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5168387A (en) * 1990-12-11 1992-12-01 Central Glass Company, Limited Variable light transmittance device
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
DK0605033T3 (da) 1992-12-21 2000-02-07 Duphar Int Res Enzymatisk fremgangsmåde til stereoselektiv fremstilling af en heterobicyklisk alkoholenantiomer
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
JP2000502066A (ja) * 1995-12-01 2000-02-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 徐放性シサプリド
JPH09315969A (ja) * 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
GB9627005D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
IL123716A (en) 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
JP2004500331A (ja) * 1999-07-13 2004-01-08 アルファ　リサーチ　グループ，　エルエルシー パーキンソン病の処置のための組成物および方法
CN100400042C (zh) * 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
EA005002B1 (ru) 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
CA2537413A1 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
CN102335116A (zh) 2003-10-29 2012-02-01 惠氏有限责任公司 包含aplindore和其衍生物的缓释药物组合物
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
EP1675583A1 (en) 2006-07-05
US20230061743A1 (en) 2023-03-02
TW200517106A (en) 2005-06-01
AU2004286855A1 (en) 2005-05-19
MXPA06004752A (es) 2006-07-05
BRPI0415953B1 (pt) 2018-12-26
KR101409724B1 (ko) 2014-06-19
HK1089394A1 (en) 2006-12-01
JP5547865B2 (ja) 2014-07-16
EP1675583B1 (en) 2013-02-27
PA8616201A1 (es) 2005-05-24
RU2006118321A (ru) 2007-12-10
US20180193311A1 (en) 2018-07-12
US20180344695A1 (en) 2018-12-06
US10463648B2 (en) 2019-11-05
CA2543045C (en) 2013-12-17
KR20060110281A (ko) 2006-10-24
PE20050484A1 (es) 2005-10-13
CN1874767A (zh) 2006-12-06
JP2007509970A (ja) 2007-04-19
IL174958A0 (en) 2008-04-13
CN102335116A (zh) 2012-02-01
BRPI0415953B8 (pt) 2021-05-25
SG147450A1 (en) 2008-11-28
AR046222A1 (es) 2005-11-30
BRPI0415953A (pt) 2007-01-02
US10292966B2 (en) 2019-05-21
US20200138781A1 (en) 2020-05-07
US11179369B2 (en) 2021-11-23
WO2005044262A1 (en) 2005-05-19
US20050095292A1 (en) 2005-05-05
AU2004286855B2 (en) 2011-04-21
RU2376988C2 (ru) 2009-12-27
NO20062004L (no) 2006-07-07
ES2405404T3 (es) 2013-05-31
IL174958A (en) 2012-08-30
CA2543045A1 (en) 2005-05-19
ZA200603409B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
GT200400218A (es) Formulaciones de liberacion sostenida.
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
MX2007010996A (es) Nuevas composiciones de liposomas.
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CR8983A (es) Capuchon para dispositivos para la adminsitracion de farmacos
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea